+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035

  • PDF Icon

    Report

  • 481 Pages
  • April 2022
  • Region: Global
  • Roots Analysis
  • ID: 5578944
Description Jump to:

Animal testing has been the most common method in various experimental studies in biomedical research, given their resemblance to humans in terms of genetics, anatomy, and physiology. Specifically, mice genome has 80% similarity with humans, which makes them excellent models for various research purposes. However, the use of animals in scientific research is associated with several ethical concerns, which led to the establishment of the principle of 3Rs- Replacement, Reduction and Refinement, to address the ethical concerns related to animal welfare and limit the use of animals in scientific research. As of 2018, this initiative led to 50% reduction in the use of animals as compared to the statistics noted in 1985. Further, the process of animal breeding / housing for scientific purposes is also associated with high costs and requires skilled labor. Moreover, it has been demonstrated that animal cell cultures are unable to accurately mimic the natural (in vivo) microenvironment as the cells cultured in monolayers are both morphologically and physiochemically different from their in vivo counterparts. These concerns have necessitated a transition from animal-based testing to the use of 3-dimensional (3D) cell culture models. Over time, advances in biotechnology and materials science have enabled the development of a variety of 3D cell culture systems in order to drive research across different application areas, including cancer research, drug discovery, tissue engineering and others. 

At present, more than 140 companies offer 3D cell culture systems in a variety of formats, including scaffold-based products, scaffold-free products and 3D bioreactors. These systems have demonstrated to be capable of more accurately simulating the natural tissue microenvironment, offer increased cell-to-cell and cell-to-ECM interactions, more accurate evaluation of drug toxicity and cellular responses, and co-cultuirng of multiple cell types together. Moreover, there are certain complex 3D cell culture models that can even replace animal models exhibiting reproducible results and thereby, serving as better in vivo models across multiple application areas. Given the various benefits of such systems, the field has garnered the attention of various venture capital firms and strategic investors that have been providing financial support to drive research efforts focused on exploring different formats of 3D cell culture systems, including organoids and organ-on-chips across multiple application areas. Moreover, there has been an increase in scientific literature on 3D cell culture systems and collaborations for 3D bioreactors and cell culture products. Given the ongoing innovation in this field, and the paradigm shift from 2D cell culture systems and animal testing to 3D cell culture models, the market is likely to witness a significant growth in the foreseen future.

Scope of the Report

The “3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (4th Edition), 2022-2035” report features an extensive study of the current landscape, offering an informed opinion on the likely evolution of the market in the mid to long term. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this domain. 

Amongst other elements, the report includes:

  • A detailed discussion on the classification of 3D cell culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. 
  • An elaborate discussion on the methods used for fabrication of 3D matrices and scaffolds, highlighting the materials used, the process of fabrication, merits and demerits, and the applications of different fabrication methods.
  • An overview of the current market landscape of companies offering various 3D cell culture systems, including information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information related to the companies providing 3D culture related services, and associated reagents / consumables.
  • A detailed assessment of the overall landscape of scaffold based products, along with analyses based on a number of relevant parameters, such as status of development (under development, developed not commercialized, and commercialized), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of scaffold (human based, chemical based, animal based, plant based, and polymer based), and fabrication material used. In addition, it presents details of the companies involved in the development of scaffold based products, providing information on their year of establishment, company size, and location of headquarters.
  • A detailed assessment of the overall landscape of scaffold free products, along with analyses based on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), type of material (human based, animal based, plant based and polymer based), and material used for fabrication. In addition, it presents details of the companies involved in the development of scaffold free products, providing information on their year of establishment, company size, and location of headquarters.
  • A detailed assessment of the overall landscape of 3D bioreactors, along with analyses based on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), status of development (under development, developed and not commercialized, and commercialized), typical working volume, scale of operation (lab scale, pre-clinical / clinical scale and commercial scale), type of manufacturing process (batch-continuous, fed-batch and continuous), type of cell culture system (mammalian cell, insect cell, microbial cell, and plant cell), type of molecule processed (vaccine, monoclonal antibody, recombinant protein, stem cell, cell therapy and gene therapy), and application area (drug discovery / toxicity testing, stem cell research, regenerative medicine / tissue engineering and cancer research). In addition, it presents details of the companies involved in the development of 3D bioreactors, providing information on their year of establishment, company size, and location of headquarters.
  • A detailed review of the key application areas (cancer research, drug discovery and toxicology, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used. 
  • Elaborate profiles of prominent players offering Scaffold-based, Scaffold-free cell culture systems and 3D bioreactors (shortlisted based on the number of products being offered) that are engaged in the development of 3D cell culture products. Each company profile includes a brief overview of the company, financial / funding information (if available), details on its product portfolio, recent developments, and an informed future outlook.
  • An analysis of the investments made in the period between 2016-2022, including instances of seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products. 
  • An analysis of the various partnerships related to 3D cell culture products, which have been established since 2015, based on several parameters, such as year of agreement, type of partnership (product development and commercialization agreements, product integration and utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.
  • An in-depth analysis of over 6,400 patents that have been filed / granted for 3D cell culture products, between 2016-2021, based on parameters, such as type of patent, publication year, issuing authority involved, CPC symbols, type of applicant, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent characteristics and geography. It also includes a detailed patent valuation analysis. 
  • An analysis of more than 3,800 peer-reviewed scientific articles related to 3D cell culture and its technologies, published since 2019, based on several parameters, such as year of publication, emerging focus areas, most popular authors, and most popular journals (in terms of number of articles published in the given time period and journal impact factor), top publisher and type of funding institute.
  • An in-depth competitiveness analysis of 3D bioreactors, taking into consideration the supplier power (based on the year of establishment of the 3D bioreactors developer) and key features of bioreactors, such as scale of operation (lab scale, pre-clinical / clinical scale and commercial scale), type of molecule supported (vaccine, monoclonal antibody, recombinant protein, stem cell, cell therapy and gene therapy), type of cell culture supported (mammalian cell, insect cell, microbial cell, and plant cell) and application area (drug discovery / toxicity testing, stem cell research, regenerative medicine/tissue engineering and cancer research).
  • A case study on the 3D cell culture products for organoids and organ-on-chips, along with analysis based on parameters, such as status of development, and area of applications. In addition, it presents details of the developer companies, along with information on their year of establishment, company size, and location of headquarters.
  • Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in the development of 3D cell culture products, emphasized on the focus area of their company, type of 3D cell culture products offered, development status of the product(s), method of fabrication used, source of 3D cultured cells, application area of product(s), type of service(s) offered, and present and future market opportunity.
  • One of the key objectives of the report was to identify the primary growth drivers and estimate the potential future size of the 3D cell culture market. Based on various parameters, such as business segment, price of 3D cell culture products, and likely adoption of the 3D cell culture products, we have developed informed estimates on the likely evolution of the 3D cell culture systems market, for the period 2022-2035. Our year-wise projections of the current and forecasted opportunity have further been segmented across 3D cell culture format (scaffold based systems, scaffold free systems, and 3D bioreactors), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), purpose (research use and therapeutic use), key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world), and leading product developers. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry.

The report features detailed transcripts of interviews held with the following industry and non-industry players: 

  • Brigitte Angres (Co-founder, Cellendes)
  • Bill Anderson (President and CEO, Synthecon)
  • Anonymous (President and CEO, Anonymous)
  • Anonymous (Co-founder and Vice President, Anonymous)
  • Scott Brush (Vice President, BRTI Life Sciences)
  • Malcolm Wilkinson (Managing Director, Kirkstall)
  • Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel)
  • Tanya Yankelevich (Director, Xylyx Bio)
  • Jens Kelm (Chief Scientific Officer, InSphero)
  • Walter Tinganelli (Group Leader, GSI)
  • Darlene Thieken (Project Manager, Nanofiber Solutions)
  • Andrea Picon (Director, Business Development, FlexCell International)
  • Frank Junker (Chief Business Officer, InSphero)
  • Mohammed Mamunur Rahman (Manager, Business Development, MBL International)

Key Questions Answered

  • Who are the leading industry players engaged in the development of 3D cell culture products?
  • Which are the most popular 3D cell culture products?
  • Which are the different application areas for which 3D cell culture products are being developed?
  • What are the key factors that are likely to influence the evolution of 3D cell culture systems market?
  • What is the trend of capital investments in the 3D cell culture systems market?
  • Which partnership models are commonly adopted by stakeholders in 3D cell culture market?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to 3D cell culture systems market?

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Cell Cultures
3.2.1. Primary Cell Cultures
3.2.2. Cell Lines
3.3. Morphology of Cells in Culture
3.4. 2D Cell Cultures vs 3D Cell Cultures
3.5. Overview of 3D Cell Culturing
3.5.1. Components of the Extracellular Matrix (ECM)
3.5.2. In Vitro Cell Culturing
3.5.3. Selection of Culture Format
3.6. Establishment and Maintenance of Cell Cultures
3.6.1. Isolating Cells from Tissues
3.6.2. Maintaining Cells in Culture
3.6.3. Sub-Culturing / Passaging
3.6.4. Cryogenic Storage
3.7. Requirements for Maintaining Healthy Cell Cultures
3.7.1. Safety Guidelines in a Cell Culture Facility
3.7.2. Cell Culture Health and Optimal Conditions for Growth
3.7.3. Cross Contamination in Cell Cultures
3.7.4. Methods to Prevent Contamination
3.8. Applications of 3D Cell Culture Systems
3.8.1. Model Systems
3.8.2. Drug Discovery and Preclinical Research
3.8.3. Cancer Research
3.8.4. Virology Research
3.8.5. Genetic Engineering and Gene Therapy Research
3.9. Advantages and Limitations of 3D Cell Culture Systems
3.10. Future Perspectives
4. CLASSIFICATION OF 3D CELL CULTURE SYSTEMS
4.1. 3D Cell Culture Classification
4.2. Scaffold Based 3D Cell Cultures
4.2.1. Hydrogels / ECM Analogs
4.2.2. Solid Scaffolds
4.2.3. Micropatterned Surfaces
4.2.4. Microcarriers
4.3. Scaffold Free 3D Cell Cultures
4.3.1. Attachment Resistant Surfaces
4.3.2. Suspension Culture Systems
4.3.2.1. Hanging Drop Plates
4.3.2.2. Magnetic Levitation and 3D Bioprinting
4.3.3. Microfluidic Surfaces and Organs-on-Chips
4.3.4. 3D Bioreactors
4.4. Organoids
5. FABRICATION OF 3D MATRICES AND SCAFFOLDS
5.1. Chapter Overview
5.2. Methods for Fabricating Porous Scaffolds
5.2.1. Particulate Leaching
5.2.2. Solvent Casting
5.2.3. Emulsion Templating
5.2.4. Gas Foaming
5.2.5. Melt Molding
5.2.6. Microsphere Sintering
5.3. Methods for Fabricating Fibrous Scaffolds
5.3.1. Electrospinning
5.3.2. Phase Separation
5.3.3. Self-Assembly
5.3.4. Fiber Mesh and Fiber Bonding
5.4. Methods for Fabricating Hydrogels
5.4.1. Gelation
5.4.2. Solvent Casting and Particulate Leaching
5.4.3. Gas Foaming
5.4.4. Freeze Drying
5.4.5. Co-polymerization / Crosslinking
5.4.6. Microfluidics
5.5. Methods for Fabricating Custom Scaffolds
5.5.1. Stereo-Lithography
5.5.2. 3D Bioprinting and Selective Laser Sintering (SLS)
5.5.3. Fused Deposition Modeling
5.5.4. Membrane Lamination
5.5.5. Rapid Prototyping / Solid Free-Form Technique
5.6. Methods for Fabricating Microspheres
5.6.1. Solvent Evaporation
5.6.2. Single and Double Emulsification
5.6.3. Particle Aggregation
5.7. Methods for Fabricating Native Scaffolds
5.7.1. Decellularization
6. 3D CELL CULTURE SYSTEMS: DEVELOPER LANDSCAPE
6.1. Chapter Overview
6.2. 3D Cell Culture System Developers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by 3D Cell Culture Format
6.2.5. Analysis by Type of Product
6.2.6. Analysis by 3D Cell Culture Format and Location of Headquarters
6.2.7. Analysis by Company Size and Type of Product
6.2.8. Analysis by Location of Headquarters
6.3. 3D Cell Cultures: List of Service Providers
6.4. 3D Cell Cultures: List of Affiliated Assays, Kits and Reagents
7. MARKET LANDSCAPE: SCAFFOLD BASED PRODUCTS
7.1. Chapter Overview
7.2. Scaffold Based Products: Overall Market Landscape
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Product
7.2.3. Analysis by Source of Scaffold
7.2.4. Analysis by Material Used for Fabrication
7.2.5. Analysis by Type of Product and Source of Scaffold
7.2.6. Analysis by Type of Product and Material Used for Fabrication
7.3. Scaffold Based Products: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Company Size and Type of Product
7.3.4. Analysis by Location of Headquarters
7.3.5. Leading Developers: Analysis by Number of Scaffold Based Products
8. MARKET LANDSCAPE: SCAFFOLD FREE PRODUCTS
8.1. Chapter Overview
8.2. Scaffold Free Products: Overall Market Landscape
8.2.1. Analysis by Status of Development
8.2.2. Analysis by Type of Product
8.2.3. Analysis by Material Used for Fabrication
8.2.4. Analysis by Material Used for Scaffold
8.2.5. Analysis by Type of Product and Material Used for Fabrication
8.3. Scaffold Free Products: Developer Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Company Size and Type of Product
8.3.4. Analysis by Location of Headquarters
8.3.5. Leading Developers: Analysis by Number of Scaffold Free Products
9. MARKET LANDSCAPE: 3D BIOREACTORS
9.1. Chapter Overview
9.2. 3D Bioreactors: Overall Market Landscape
9.2.1. Analysis by Type of 3D Bioreactor
9.2.2. Analysis by Status of Development
9.2.3. Analysis by Working Volume
9.2.4. Analysis by Scale of Operation
9.2.5. Analysis by Manufacturing Process
9.2.6. Analysis by Type of Cell Culture System
9.2.7. Analysis by Type of Molecule Processed
9.2.8. Analysis by Area of Application
9.3. 3D Bioreactors: Developer Landscape
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
9.3.4. Leading Developers: Analysis by Number of 3D Bioreactors
10. KEY APPLICATION AREAS
10.1. Chapter Overview
10.2. 3D Cell Culture Systems in Cancer Research
10.2.1. Need for 3D Culture Systems in Cancer Research
10.2.1.1. Cancer Drug Screening with 3D Culture Systems
10.3. 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
10.3.1. Drug Development Studies
10.3.2. Toxicity Screening
10.3.2.1. 3D Liver Models
10.3.2.2. Other 3D Models
10.4. 3D Cell Culture Systems in Stem Cell Research
10.4.1. 3D Culture Systems in Stem Cell Differentiation
10.4.2. In Vitro 3D Microenvironment to Induce Embryoid Body Formation
10.5. 3D Cell Cultures in Regenerative Medicine and Tissue Engineering
10.6. 3D Cell Culture Systems: Analysis by Key Application Areas
10.6.1. 3D Cell Culture Systems: Analysis by Key Application Areas and 3D Cell Culture Format
10.6.1.1. Scaffold Based 3D Products: Analysis by Key Application Areas
10.6.1.2. Scaffold Free 3D Products: Analysis by Key Application Areas
10.6.1.3. 3D Bioreactors: Analysis by Key Application Areas
11. COMPANY PROFILES: SCAFFOLD BASED PRODUCTS (HYDROGEL / ECM DEVELOPERS)
11.1. Chapter Overview
11.1.1. 3D Biotek
11.1.1.1. Company Overview
11.1.1.2. Product Portfolio
11.1.1.3. Recent Developments and Future Outlook
11.1.2. Advanced BioMatrix
11.1.2.1. Company Overview
11.1.2.2. Product Portfolio
11.1.2.3. Recent Development and Future Outlook
11.1.3. Alphabioregen
11.1.3.1. Company Overview
11.1.3.2. Product Portfolio
11.1.3.3. Recent Developments and Future Outlook
11.1.4. Corning Life Sciences
11.1.4.1. Company Overview
11.1.4.2. Product Portfolio
11.1.4.3. Recent Developments and Future Outlook
11.1.5. REPROCELL
11.1.5.1. Company Overview
11.1.5.2. Product Portfolio
11.1.5.3. Recent Developments and Future Outlook
12. COMPANY PROFILES: SCAFFOLD FREE PRODUCTS (ORGAN-ON-CHIPS DEVELOPERS)
12.1. Chapter Overview
12.1.1. CN Bio Innovations
12.1.1.1. Company Overview
12.1.1.2. Financial Information
12.1.1.3. Product Portfolio
12.1.1.4. Recent Developments and Future Outlook
12.1.2. Emulate
12.1.2.1. Company Overview
12.1.2.2. Financial Information
12.1.2.3. Product Portfolio
12.1.2.4. Recent Developments and Future Outlook
12.1.3. InSphero
12.1.3.1. Company Overview
12.1.3.2. Financial Information
12.1.3.3. Product Portfolio
12.1.3.4. Recent Developments and Future Outlook
12.1.4. MIMETAS
12.1.4.1. Company Overview
12.1.4.2. Financial Information
12.1.4.3. Product Portfolio
12.1.4.4. Recent Developments and Future Outlook
12.1.5. TissUse
12.1.5.1. Company Overview
12.1.5.2. Product Portfolio
12.1.5.3. Recent Developments and Future Outlook
13. COMPANY PROFILES: 3D BIOREACTORS
13.1. Chapter Overview
13.2. BISS TGT
13.2.1. Company Overview
13.2.2. Product Portfolio
13.2.3. Recent Developments and Future Outlook
13.3. Celartia
13.3.1. Company Overview
13.3.2. Product Portfolio
13.3.3. Recent Developments and Future Outlook
13.4. Cell Culture
13.4.1. Company Overview
13.4.2. Product Portfolio
13.4.3. Recent Developments and Future Outlook
13.5. EBERS
13.5.1. Company Overview
13.5.2. Product Portfolio
13.5.3. Recent Developments and Future Outlook
13.6. Flexcell International
13.6.1. Company Overview
13.6.2. Product Portfolio
13.6.3. Recent Developments and Future Outlook
13.7. PBS Biotech
13.7.1. Company Overview
13.7.2. Product Portfolio
13.7.3. Recent Developments and Future Outlook
13.8. Synthecon
13.8.1. Company Overview
13.8.2. Product Portfolio
13.8.3. Recent Developments and Future Outlook
14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. 3D Cell Culture Systems: Funding and Investment Analysis
14.3.1. Analysis by Number of Funding Instances
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by 3D Cell Culture Format
14.3.5. Analysis by Type of Product
14.3.6. Analysis by Geography
14.3.7. Most Active Players: Analysis by Number of Funding Instances
14.3.8. Most Active Players: Analysis by Amount of Funding
14.3.9. Most Active Investors: Analysis by Number of Instances
14.4 Summary of Funding and Investments
15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. 3D Cell Culture Systems: List of Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.2.1. Analysis by Year of Partnership and Type of Partnership
15.3.2.2. Analysis by Company Size and Type of Partnership
15.3.3. Analysis by Type of Partner
15.3.3.1. Analysis by Year of Partnership and Type of Partner
15.3.3.2. Analysis by Type of Partnership and Type of Partner
15.3.4. Analysis by 3D Cell Culture Format
15.3.4.1. Analysis by Year of Partnership and 3D Cell Culture Format
15.3.4.2. Analysis by Type of Partnership and 3D Cell Culture Format
15.3.5. Analysis by Type of Product
15.3.5.1. Analysis by Year of Partnership and Type of Product
15.3.5.2. Analysis by Type of Partnership and Type of Product
15.3.6. Most Active Players: Analysis by Number of Partnerships
15.3.7. Regional Analysis
15.3.8. Intercontinental and Intracontinental Agreements
16. PATENT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. 3D Cell Culture Systems: Patent Analysis
16.3.1. Analysis by Type of Patent
16.3.2. Analysis by Publication Year
16.3.3. Analysis by Type of Patent and Publication Year
16.3.3. Analysis by Issuing Authority
16.3.4. Analysis by CPC Symbols
16.3.5. Analysis by Type of Applicant
16.3.6. Word Cloud Analysis: Emerging Focus Areas
16.3.7. Leading Industry Players: Analysis by Number of Patents
16.3.8. Leading Non-Industry Players: Analysis by Number of Patents
16.4. 3D Cell Culture Systems: Patent Valuation Analysis
16.5. Leading Patents: Analysis by Number of Citations
17. PUBLICATION ANALYSIS
17.1. 3D Cell Culture Systems: Publication Analysis
17.2. Assumptions and Key Parameters
17.3. Methodology
17.3.1. Analysis by Year of Publication
17.3.2. Word Cloud Analysis: Emerging Focus Areas
17.3.3. Top Authors: Analysis by Number of Publications
17.3.4. Key Journals: Analysis by Number of Publications
17.3.5. Key Publishers: Analysis by Number of Publications
17.3.6. Leading Funding Institutes: Analysis by Number of Publications
18. PRODUCT COMPETITIVENESS ANALYSIS
18.1. Chapter Overview
18.2. Assumptions / Key Parameters
18.3. Methodology
18.4. Product Competitiveness Analysis: 3D Bioreactors
18.4.1. Companies Headquartered in North America
18.4.2. Companies Headquartered in Europe
18.4.3. Companies Headquartered in Asia-Pacific and Rest of the World
19. CASE STUDY: ORGANIDS AND ORGAN-ON-CHIPS
19.1. Chapter Overview
19.2. Organoids and Organ-on-Chips: List of Products
19.2.1. Analysis by Status of Development
19.2.2. Analysis by Application Area
19.3. Organoids and Organ-on-Chips: List of Product Developers
19.3.1. Analysis by Year of Establishment
19.3.2. Analysis by Company Size
19.3.3. Analysis by Location of Headquarters
20. MARKET FORECAST
20.1. Chapter Overview
20.2. Key Assumptions and Forecast Methodology
20.3. Global 3D Cell Culture Market, 2022-2035
20.4. Global 3D Cell Culture Market: Distribution by Business Segment
20.4.1. 3D Cell Culture Systems Market, 2022-2035
20.4.2. 3D Cell Culture Consumables Market, 2022-2035
20.4.3. 3D Cell Culture Services Market, 2022-2035
20.5. Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format
20.5.1. 3D Cell Culture Systems Market for Scaffold Based Products, 2022-2035
20.5.2. 3D Cell Culture Systems Market for Scaffold Free Products, 2022-2035
20.5.3. 3D Cell Culture Systems Market for 3D Bioreactors, 2022-2035
20.6. Global 3D Cell Culture Systems Market: Distribution by Type of Product
20.6.1. 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2022-2035
20.6.2. 3D Cell Culture Systems Market for Hydrogels / ECMs, 2022-2035
20.6.3 3D Cell Culture Systems Market for Micropatterned Surface, 2022-2035
20.6.4. 3D Cell Culture Systems Market for Microcarriers, 2022-2035
20.6.5. 3D Cell Culture Systems Market for Microfluidic Systems, 2022-2035
20.6.6. 3D Cell Culture Systems Market for Solid Scaffolds, 2022-2035
20.6.7. 3D Cell Culture Systems Market for Suspension Culture Systems, 2022-2035
20.7. Global 3D Cell Culture Systems Market: Distribution by Area of Application
20.7.1. 3D Cell Culture Systems Market for Cancer Research, 2022-2035
20.7.2 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2022-2035
20.7.3. 3D Cell Culture Systems Market for Stem Cell Research, 2022-2035
20.7.4. 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2022-2035
20.8. Global 3D Cell Culture Systems Market: Distribution by Purpose
20.8.1. 3D Cell Culture Systems Market for Research Use, 2022-2035
20.8.2 3D Cell Culture Systems Market for Therapeutic Use, 2022-2035
20.9. Global 3D Cell Culture Systems Market: Distribution by Geography
20.9.1. 3D Cell Culture Systems Market in North America, 2022-2035
20.9.2 3D Cell Culture Systems Market in Europe, 2022-2035
20.9.3. 3D Cell Culture Systems Market in Asia-Pacific, 2022-2035
20.9.4. 3D Cell Culture Systems Market in Latin America, 2022-2035
20.9.5. 3D Cell Culture Systems Market in Middle East and North Africa, 2022-2035
20.9.6. 3D Cell Culture Systems Market in Rest of the World, 2022-2035
21. SURVEY ANALYSIS
21.1. Chapter Overview
21.2. Overview of Respondents
21.2.1. Designation of Respondents
21.3. Survey Insights
21.3.1. 3D Cell Culture Format
21.3.2. Type of Product(s) Offered
21.3.3. Status of Development of Product(s)
21.3.4. Source of 3D Cultured Cells
21.3.5. Method Used for Fabrication
21.3.6. Area(s) of Application
21.3.7. Services Offered for 3D Cell Cultures
21.3.8. Current and Future Market Opportunity
22. CONCLUSION
23. EXECUTIVE INSIGHTS
23.1. Chapter Overview
23.2. Cellendes
23.2.1. Company Snapshot
23.2.2. Interview Transcript: Brigitte Angres, Co-founder
23.3. Synthecon
23.3.1. Company Snapshot
23.3.2. Interview Transcript: Bill Anderson, President and Chief Executive Officer
23.4. Anonymous
23.4.1. Interview Transcript: Anonymous, President and Chief Executive Officer
23.5. Anonymous
23.5.1. Interview Transcript: Anonymous, Co-founder and Vice President
23.6. BRTI Life Sciences
23.6.1. Company Snapshot
22.6.2. Interview Transcript: Scott Brush, Vice President
23.7. Kirkstall
23.7.1. Company Snapshot
23.7.2. Interview Transcript: Malcolm Wilkinson, Non-Executive Director
23.8. QGel
23.8.1. Company Snapshot
23.8.2. Interview Transcript: Ryder Clifford, Chief Executive Officer and Simone Carlo Rizzi, Chief Scientific Officer
23.9. Xylyx Bio
23.9.1. Company Snapshot
23.9.2. Interview Transcript: Tanya Yankelevich, Former Director of Product Management and Business Development
23.10. InSphero
23.10.1. Company Snapshot
23.10.2. Interview Transcript: Jens Kelm, Former Chief Scientific Officer
23.11. GSI
23.11.1. Company Snapshot
23.11.2. Interview Transcript: Walter Tinganelli, Group Leader, Clinical Radiobiology
23.12. Nanofiber Solutions
23.12.1. Company Snapshot
23.12.2. Interview Transcript: Darlene Thieken, Former Project Manager
23.13. FlexCell International
23.13.1. Company Snapshot
23.13.2. Interview Transcript: Andrea Picon, Director of Business Development
23.14. InSphero
23.14.1. Company Snapshot
23.14.2. Interview Transcript: Frank Junker, Chief Business officer
23.15. MBL International
23.15.1. Company Snapshot
23.15.2. Interview Transcript: Mamun, Rahman, Manger, Business Development
24. APPENDIX I: TABULATED DATA25. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
Figure 3.1 Classification of Cell Cultures
Figure 3.2 Types of Cell Cultures
Figure 3.3 Key Components of ECM
Figure 3.4 Factors Influencing the Selection of 3D Cell Culture Systems
Figure 3.5 Methods Used for Isolation of Cells from Tissues
Figure 3.6 Methods Used for Cryogenic Storage of Cell Cultures
Figure 3.7 Biosafety Levels for Cell Cultures
Figure 3.8 Key Applications of Cell Cultures
Figure 3.9 Shapes of 3D Spheroids Generated via 3D Cell Culture Systems
Figure 3.10 Advantages and Limitations of 3D Cell Culture Systems
Figure 4.1 Classification of 3D Cell Culture Systems
Figure 4.2 Natural Components of ECM Used for Fabrication of Scaffolds
Figure 4.3 Advantages and Disadvantages of Hydrogels
Figure 4.4 Advantages of Microcarriers
Figure 4.5 Techniques Used for Formation of 3D Spheroids
Figure 4.6 Structures of Spinner Flask and Rotating Wall Bioreactors
Figure 6.1 3D Cell Culture System Developers: Distribution by Year of Establishment
Figure 6.2 3D Cell Culture System Developers: Distribution by Company Size
Figure 6.3 3D Cell Culture System Developers: Distribution by Location of Headquarters
Figure 6.4 3D Cell Culture System Developers: Distribution by 3D Cell Culture Format
Figure 6.5 3D Cell Culture System Developers: Distribution by Type of Product
Figure 6.6 Heat Map Representation: Distribution by 3D Cell Culture Format and Location of Headquarters
Figure 6.7 Tree Map Representation: Distribution by Company Size and Type of Product
Figure 6.8 World Map Representation: Distribution by Location of Headquarters
Figure 7.1 Scaffold Based Products: Distribution by Status of Development
Figure 7.2 Scaffold Based Products: Distribution by Type of Product
Figure 7.3 Scaffold Based Products: Distribution by Source of Scaffold
Figure 7.4 Scaffold Based Products: Distribution by Material Used for Fabrication
Figure 7.5 Scaffold Based Products: Distribution by Type of Product and Source of Scaffold
Figure 7.6 Scaffold Based Products: Distribution by Type of Product and Material Used for Fabrication
Figure 7.7 Scaffold Based Product Developers: Distribution by Year of Establishment
Figure 7.8 Scaffold Based Product Developers: Distribution by Company Size
Figure 7.9 Scaffold Based Product Developers: Distribution by Location of Headquarters
Figure 7.10 Leading Developers: Distribution by Number of Scaffold Based Products
Figure 7.11 Tree Map Representation: Distribution by Company Size and Type of Product
Figure 8.1 Scaffold Free Products: Distribution by Status of Development
Figure 8.2 Scaffold Free Products: Distribution by Type of Product
Figure 8.3 Scaffold Free Products: Distribution by Method Used for Fabrication
Figure 8.4 Scaffold Free Products: Distribution by Material Used for Fabrication
Figure 8.5 Scaffold Free Products: Distribution by Type of Product and Material Used for Fabrication
Figure 8.6 Scaffold Free Product Developers: Distribution by Year of Establishment
Figure 8.7 Scaffold Free Product Developers: Distribution by Company Size
Figure 8.8 Scaffold Free Product Developers: Distribution by Location of Headquarters
Figure 8.9 Leading Developers: Distribution by Number of Scaffold Free Products
Figure 8.10 Tree Map Representation: Distribution by Company Size and Type of Product
Figure 9.1 3D Bioreactors: Distribution by Type of 3D Bioreactor
Figure 9.2 3D Bioreactors: Distribution by Status of Development
Figure 9.3 3D Bioreactors: Distribution by Working Volume
Figure 9.4 3D Bioreactors: Distribution by Scale of Operation
Figure 9.5 3D Bioreactors: Distribution by Manufacturing Process
Figure 9.6 3D Bioreactors: Distribution by Type of Cell Culture System
Figure 9.7 3D Bioreactors: Distribution by Type of Molecule Processed
Figure 9.8 3D Bioreactors: Distribution by Area of Application
Figure 9.9 3D Bioreactor Developers: Distribution by Year of Establishment
Figure 9.10 3D Bioreactor Developers: Distribution by Company Size
Figure 9.11 3D Bioreactor Developers: Distribution by Location of Headquarters
Figure 9.12 Leading Developers: Distribution by Number of 3D Bioreactors
Figure 10.1 Key Application Areas of 3D Cell Culture Systems
Figure 10.2 3D Cell Culture Systems in Cancer Research
Figure 10.3 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
Figure 10.4 Methods to Generate Embryoid Bodies
Figure 10.5 Top-Down and Bottom-Up Approaches for Tissue Engineering
Figure 10.6 3D Cell Culture Systems: Distribution by Key Application Areas
Figure 10.7 3D Cell Culture Systems: Distribution by Key Application Areas and 3D Cell Culture Format
Figure 10.8 Scaffold Based 3D Products: Distribution by Key Application Areas
Figure 10.9 Scaffold Free 3D Products: Distribution by Key Application Areas
Figure 10.10 3D Bioreactors: Distribution by Key Application Areas
Figure 13.1 Key Features of 3D Perfusion Bioreactors
Figure 13.2 MagDrive and AirDrive Mechanisms for PBS Bioreactors
Figure 13.3 Advantages of Rotary Cell Culture System (RCCS)
Figure 14.1 Funding and Investments: Distribution of Recipient Companies by Year of Establishment and Type of Funding, 2015 - 2021
Figure 14.2 Funding and Investments: Cumulative Number of Funding Instances by Year, 2015 - 2021
Figure 14.3 Funding and Investments: Cumulative Amount Invested, 2015 - 2021 (USD Million)
Figure 14.4 Funding and Investments: Distribution of Instances by Type of Funding, 2015 -2021
Figure 14.5 Funding and Investments: Year-Wise Distribution of Instances and Type of Funding, 2015 - 2021
Figure 14.6 Funding and Investments: Distribution by Amount Invested and Type of Funding, 2015 - 2021 (USD Million)
Figure 14.7 Funding and Investments: Year-Wise Distribution of Amount Invested and Type of Funding, 2015 - 2021
Figure 14.8 Funding and Investments: Distribution by Number of Instances and Amount Invested by 3D Cell Culture Format, 2015 - 2021
Figure 14.9 Funding and Investments: Distribution by Number of Instances and Amount Invested by Type of Product, 2015 - 2021
Figure 14.10 Funding and Investments: Distribution by Geography
Figure 14.11 Funding and Investments: Regional Distribution by Total Amount Invested, 2015 - 2021
Figure 14.12 Most Active Players: Distribution by Number of Funding Instances, 2015 -2021
Figure 14.13 Most Active Players: Distribution by Amount Raised, 2015 - 2021 (USD Million)
Figure 14.14 Most Active Investors: Distribution by Number of Funding Instances, 2015 -2021
Figure 14.15 Funding and Investment Summary, 2015 - 2021 (USD Million)
Figure 15.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015 - 2021
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 15.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 15.4 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Figure 15.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 15.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 15.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 15.8 Partnerships and Collaborations: Distribution by 3D Cell Culture Format
Figure 15.9 Partnerships and Collaborations: Distribution by Year of Partnership and 3D Cell Culture Format
Figure 15.10 Partnerships and Collaborations: Distribution by Type of Partnership and 3D Cell Culture Format
Figure 15.11 Partnerships and Collaborations: Distribution by Type of Product
Figure 15.12 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
Figure 15.13 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 15.14 Most Active Players: Distribution by Number of Partnerships
Figure 15.15 Partnerships and Collaborations: Regional Distribution
Figure 15.16 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 16.1 Patent Analysis: Distribution by Type of Patent
Figure 16.2 Patent Analysis: Cumulative Distribution by Publication Year, 2016 - Q1 2022
Figure 16.3 Patent Analysis: Distribution of Granted Patents by Publication Year, 2016 - Q1 2022
Figure 16.4 Patent Analysis: Distribution of Filed Patents Publication Year, 2016 - Q1 2022
Figure 16.5 Patent Analysis: Distribution by Type of Patent and Publication Year, 2016 - Q1 2022
Figure 16.6 Patent Analysis: Distribution by Issuing Authority
Figure 16.7 Patent Analysis: Distribution by CPC Symbols
Figure 16.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2016 - Q1 2022
Figure 16.9 Word Cloud Analysis: Distribution by Emerging Focus Area
Figure 16.10 Leading Industry Players: Distribution by Number of Patents
Figure 16.11 Leading Non-Industry Players: Distribution by Number of Patents
Figure 16.12 Patent Analysis: Distribution by Patent Age, 2002-2022
Figure 16.13 Patent Analysis: Distribution by Relatuve Valuation
Figure 17.1 Publication Analysis: Distribution by Year of Publication
Figure 17.2 Word Cloud Analysis: Emerging Focus Areas
Figure 17.3 Top Authors: Distribution by Number of Publications
Figure 17.4 Key Journals: Distribution by Number of Publications
Figure 17.5 Key Publishers: Distribution by Number of Publications
Figure 17.6 Leading Funding Institutes: Distribution by Number of Publications
Figure 18.1 Competitiveness Analysis: 3D Bioreactors Developers based in North America
Figure 18.2 Competitiveness Analysis: 3D Bioreactors Developers based in Europe
Figure 18.3 Competitiveness Analysis: 3D Bioreactors Developers based in Asia-Pacific and Rest of the World
Figure 19.1 Organoids and Organ-on-Chips: Distribution by Status of Development
Figure 19.2 Organoids and Organ-on-Chips: Distribution by Application Area
Figure 19.3 Organoids and Organ-on-Chips Developers: Distribution by Year of Establishment
Figure 19.4 Organoids and Organ-on-Chips Developers: Distribution by Company Size
Figure 19.5 Organoids and Organ-on-Chips Developers: Distribution by Location of Headquarters
Figure 20.1 Global 3D Cell Culture Market, 2022-2035 (USD Million)
Figure 20.2 Global 3D Cell Culture Market: Distribution by Business Segment, 2022 and 2035
Figure 20.3 3D Cell Culture Systems Market, 2022-2035 (USD Million)
Figure 20.4 3D Cell Culture Consumables Market, 2022-2035 (USD Million)
Figure 20.5 3D Cell Culture Services Market, 2022-2035 (USD Million)
Figure 20.6. Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format, 2022-2035
Figure 20.7 3D Cell Culture Systems Market for Scaffold Based Products, 2022-2035 (USD Million)
Figure 20.8 3D Cell Culture Systems Market for Scaffold Free Products, 2022-2035 (USD Million)
Figure 20.9 3D Cell Culture Systems Market for 3D Bioreactors, 2022-2035 (USD Million)
Figure 20.10 Global 3D Cell Culture Systems Market: Distribution by Type of Product, 2022 and 2035
Figure 20.11 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2022-2035 (USD Million)
Figure 20.12 3D Cell Culture Systems Market for Hydrogels / ECMs, 2022-2035 (USD Million)
Figure 20.13 3D Cell Culture Systems Market for Micropatterned Surface, 2022-2035 (USD Million)
Figure 20.14 3D Cell Culture Systems Market for Microcarriers, 2022-2035 (USD Million)
Figure 20.15 3D Cell Culture Systems Market for Microfluidic Systems, 2022-2035 (USD Million)
Figure 20.16 3D Cell Culture Systems Market for Solid Scaffolds, 2022-2035 (USD Million)
Figure 20.17 3D Cell Culture Systems Market for Suspension Cultures, 2022-2035 (USD Million)
Figure 20.18 Global 3D Cell Culture Systems Market: Distribution by Area of Application, 2022 and 2035
Figure 20.19 3D Cell Culture Systems Market for Cancer Research, 2022-2035 (USD Million)
Figure 20.20 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2022-2035 (USD Million)
Figure 20.21 3D Cell Culture Systems Market for Stem Cell Research, 2022-2035 (USD Million)
Figure 20.22 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2022-2035 (USD Million)
Figure 20.23 Global 3D Cell Culture Systems Market: Distribution by Purpose, 2022 and 2035
Figure 20.24 3D Cell Culture Systems Market for Research Use, 2022-2035 (USD Million)
Figure 20.25 3D Cell Culture Systems Market for Therapeutic Use, 2022-2035 (USD Million)
Figure 20.26 Global 3D Cell Culture Systems Market: Distribution by Geography, 2022 and 2035
Figure 20.27 3D Cell Culture Systems Market in North America, 2022-2035 (USD Million)
Figure 20.28 3D Cell Culture Systems Market in Europe, 2022-2035 (USD Million)
Figure 20.29 3D Cell Culture Systems Market in Asia-Pacific, 2022-2035 (USD Million)
Figure 20.30 3D Cell Culture Systems Market in Latin America, 2022-2035 (USD Million)
Figure 20.31 3D Cell Culture Systems Market in Middle East and North Africa (MENA), 2022-2035 (USD Million)
Figure 20.32 3D Cell Culture Systems Market in Rest of the World, 2022-2035 (USD Million)
Figure 20.33 Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2022
Figure 20.34 Global 3D Cell Culture Systems Market: Conservative, Base and Optimistic Scenarios, 2022, 2028 and 2035 (USD Million)
Figure 21.1 Survey Insights: Distribution of Respondents by Year of Establishment of the Company
Figure 21.2 Survey Insights: Distribution of Respondents by Company Size
Figure 21.3 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Region-Wise)
Figure 21.4 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
Figure 21.5 Survey Insights: Distribution of Respondents by Designation and Seniority Level
Figure 21.6 Survey Insights: Distribution by Focus Area
Figure 21.7 Survey Insights: Distribution by Type of 3D Cell Culture Products Offered
Figure 21.8 Survey Insights: Distribution by Status of Development of Product(s)
Figure 21.9 Survey Insights: Distribution by Method of Fabrication Used
Figure 21.10 Survey Insights: Distribution by Source of Cultured Cells
Figure 21.11 Survey Insights: Distribution by Key Applications
Figure 21.12 Survey Insights: Distribution by 3D Cell Culture Services Offered
Figure 21.13 Survey Insights: Distribution by Current and Future Market Opportunity, 2022 and 2035
Figure 22.1 Concluding Remarks: Overall Market Landscape of 3D Cell Culture Systems Market
Figure 22.2 Concluding Remarks: Funding and Investments
Figure 22.3 Concluding Remarks: Partnerships and Collaborations
Figure 22.4 Concluding Remarks: Patent Analysis
Figure 22.5 Concluding Remarks: Publication Analysis
Figure 22.6 Concluding Remarks: Market Sizing and Opportunity Analysis
List Of Tables
Table 3.1 Morphology of Cells in a Culture
Table 3.2 Differences between 2D and 3D Cell Cultures
Table 3.3 Features of 3D Spheroids generated via 3D Cell Culture Systems
Table 4.1 Advantages and Disadvantages of Scaffold Based and Scaffold Free Systems
Table 4.2 Advantages and Disadvantages of Natural and Synthetic Scaffolds
Table 4.3 Advantages and Disadvantages of Natural and Synthetic Hydrogels
Table 4.4 Cell Cultures Used in Magnetic Levitation
Table 4.5 Origin and Culture Techniques Used for Organoids
Table 5.1 Advantages and Disadvantages of Methods Used for Fabrication for Porous Scaffolds
Table 5.2 3D Cell Culture Studies Using Porous Scaffolds
Table 5.3 Methods for Fabrication Used of Fibrous Scaffolds
Table 5.4 Advantages and Disadvantages of Methods Used for Fabrication of Fibrous Scaffolds
Table 5.5 3D Cell Culture Studies Using Fibrous Scaffolds
Table 5.6 Advantages and Disadvantages of Methods Used for Fabrication of Hydrogels
Table 5.7 3D Cell Culture Studies Using Hydrogels
Table 5.8 Advantages and Disadvantages of Methods Used for Fabrication of Custom Scaffolds
Table 5.9 3D Cell Culture Studies Using Custom Scaffolds
Table 5.10 Advantages and Disadvantages of Methods Used for Fabrication of Microspheres
Table 5.11 3D Cell Culture Studies Using Microspheres
Table 5.12 3D Cell Culture Studies Using Native Scaffolds
Table 6.1 3D Cell Culture Systems: List of Developers
Table 6.2 3D Cell Culture Systems: List of Service Providers
Table 6.3 3D Cell Culture Systems: List of Assays, Kits and Reagents
Table 7.1 Scaffold Based Products: List of Products
Table 7.2 Scaffold Based Products: List of Developers
Table 8.1 Scaffold Free Products: List of Products
Table 8.2 Scaffold Free Products: List of Developers
Table 9.1 3D Bioreactors: List of Products
Table 9.2 3D Bioreactors: List of Developers
Table 10.1 Scaffold Based Products: Information on Key Application Areas
Table 10.2 Scaffold Free Products: Information on Key Application Areas
Table 10.3 3D Bioreactors: Information on Key Application Areas
Table 11.1 Scaffold Based Products (Hydrogel / ECM Developers): List of Companies Profiled
Table 11.2 3D Biotek: Company Snapshot
Table 11.3 3D Biotek: Key Characteristics of Hydrogels / ECMs
Table 11.4 3D Biotek: Recent Developmnets and Future Outlook
Table 11.5 Advanced BioMatrix: Company Snapshot
Table 11.6 Advanced BioMatrix: Key Characteristics of Hydrogels / ECMs
Table 11.7 Advanced BioMatrix: Recent Developments and Future Outlook
Table 11.8 Alphabioregen: Company Snapshot
Table 11.9 Alphabioregen: Key Characteristics of Hydrogels / ECMs
Table 11.10 Alphabioregen: Recent Developments and Future Outlook
Table 11.11 Corning Life Sciences: Company Snapshot
Table 11.12 Corning Life Sciences: Key Characteristics of Hydrogels / ECMs
Table 11.13 Corning Life Sciences: Recent Developments and Future Outlook
Table 11.14 REPROCELL: Company Snapshot
Table 11.15 REPROCELL: Key Characteristics of Hydrogels / ECMs
Table 11.16 REPROCELL: Recent Developments and Future Outlook
Table 12.1 Scaffold Free Products (Organ-on-Chips): List of Companies Profiled
Table 12.2 CN Bio Innovations: Company Snapshot
Table 12.3 CN Bio Innovations: Information on Financial Instances
Table 12.4 CN Bio Innovations: Key Characteristics of Organ-on-Chips Products
Table 12.5 CN Bio Innovations: Recent Developments and Future Outlook
Table 12.6 Emulate: Company Snapshot
Table 12.7 Emulate: Information on Funding Instances
Table 12.8 Emulate: Key Characteristics of Organ-on-Chips Products
Table 12.9 Emulate: Recent Developments and Future Outlook
Table 12.10 InSphero: Company Snapshot
Table 12.11 InSphero: Information on Funding Instances
Table 12.12 InSphero: Key Characteristics of Organ-on-Chips Products
Table 12.13 InSphero: Recent Developments and Future Outlook
Table 12.14 MIMETAS: Company Snapshot
Table 12.15 MIMETAS: Information on Funding Instances
Table 12.16 MIMETAS: Key Characteristics of Organ-on-Chips Products
Table 12.17 MIMETAS: Recent Developments and Future Outlook
Table 12.18 TissUse: Company Snapshot
Table 12.19 TissUse: Key Characteristics of Organ-on-Chips Products
Table 12.20 TissUse: Recent Developments and Future Outlook
Table 13.1 3D Bioreactors: List of Companies Profiled
Table 13.2 BISS TGT: Company Snapshot
Table 13.3 BISS TGT: Key Characteristics of 3D Bioreactors
Table 13.4 BISS TGT: Recent Developments and Future Outlook
Table 13.5 Celartia: Company Snapshot
Table 13.6 Celartia: Key Characteristics of 3D Bioreactors
Table 13.7 Celartia: Recent Developments and Future Outlook
Table 13.8 Cell Culture: Company Snapshot
Table 13.9 Cell Culture: Key Characteristics of 3D Bioreactors
Table 13.10 EBERS: Company Snapshot
Table 13.11 EBERS: Key Characteristics of 3D Bioreactors
Table 13.12 EBERS: Recent Developments and Future Outlook
Table 13.13 Flexcell International: Company Snapshot
Table 13.14 Flexcell International: Key Characteristics of 3D Bioreactors
Table 13.15 Flexcell International: Recent Developments and Future Outlook
Table 13.16 PBS Biotech: Company Snapshot
Table 13.17 PBS Biotech: Key Characteristics of 3D Bioreactors
Table 13.18 PBS Biotech: Recent Developments and Future Outlook
Table 13.19 Synthecon: Company Snapshot
Table 13.20 Synthecon: Key Characteristics of 3D Bioreactors
Table 13.21 Synthecon: Recent Developments and Future Outlook
Table 14.1 Funding and Investments: Information on Year of Investment, Type of Funding, Amount Raised and Investor, 2016 - 2021
Table 14.2 Funding and Investments: Information on Year of Establishment, Location of Headquarters of Recipients, Focus Area, and Type of Product, 2016 -2021
Table 15.1 Partnerships and Collaborations: Information on Year of Partnership, Type of Partnership, and Partner, 2016 - Q1 2022
Table 15.2 Partnerships and Collaborations: Information on Type of Agreement, Focus Area, and Type of Product, 2016 - Q1 2022
Table 16.1 Patent Analysis: CPC Symbols
Table 16.2 Patent Analysis: Most Popular CPC Symbols
Table 16.3 Patent Analysis: List of Top 10 CPC Symbols
Table 16.4 Patent Analysis: List of Relatively High Value Patents
Table 18.1 Survey Insights: Overview of Respondents
Table 18.2 Survey Insights: Designation and Seniority Level
Table 18.3 Survey Insights: Focus Area of the Company
Table 18.4 Survey Insights: Type of 3D Cell Culture Products Offered
Table 18.5 Survey Insights: Status of Development of Product(s)
Table 18.6 Survey Insights: Method of Fabrication Used
Table 18.7 Survey Insights: Source of 3D Cultured Cells
Table 18.8 Survey Insights: Key Areas of Application
Table 18.9 Survey Insights: 3D Cell Culture Services Offered
Table 18.10 Survey Insights: Current Market Opportunity (2022)
Table 18.11 Survey Insights: Future Market Opportunity (2035)
Table 20.1 Cellendes: Company Snapshot
Table 20.2 Synthecon: Company Snapshot
Table 20.3 BRTI Life Sciences: Company Snapshot
Table 20.4 Kirkstall: Company Snapshot
Table 20.5 QGel: Company Snapshot
Table 20.6 Xylyx Bio: Company Snapshot
Table 20.7 InSphero: Company Snapshot
Table 20.8 GSI: Company Snapshot
Table 20.9 Nanofiber Solutions: Company Snapshot
Table 20.10 FlexCell International: Company Snapshot
Table 20.11 MBL International: Company Snapshot
Table 21.1 3D Cell Culture System Developers: Distribution by Year of Establishment
Table 21.2 3D Cell Culture System Developers: Distribution by Company Size
Table 21.3 3D Cell Culture System Developers: Distribution by Location of Headquarters
Table 21.4 3D Cell Culture System Developers: Distribution by 3D Cell Culture Format
Table 21.5 3D Cell Culture System Developers: Distribution by Type of Product
Table 21.6 3D Cell Culture System Developers: Distribution by Number of Products
Table 21.7 Heat Map Representation: Distribution by 3D Cell Culture Format and Location of Headquarters
Table 21.8 Tree Map Representation: Distribution by Company Size and Type of Product
Table 21.9 World Map Representation: Distribution by Location of Regional Headquarters
Table 21.10 Scaffold Based Products: Distribution by Status of Development
Table 21.11 Scaffold Based Products: Distribution by Type of Product
Table 21.12 Scaffold Based Products: Distribution by Source of 3D Cultured Cells
Table 21.13 Scaffold Based Products: Distribution by Method Used for Fabrication
Table 21.14 Scaffold Based Products: Distribution by Material Used for Fabrication
Table 21.15 Scaffold Based Products: Distribution by Type of Product and Source of 3D Cultured Cells
Table 21.16 Scaffold Based Products: Distribution by Type of Product and Method Used for Fabrication
Table 21.17 Scaffold Based Product Developers: Distribution by Year of Establishment
Table 21.18 Scaffold Based Product Developers: Distribution by Company Size
Table 21.19 Scaffold Based Product Developers: Distribution by Location of Headquarters
Table 21.20 Leading Developers: Distribution by Number of Scaffold Based Products
Table 21.21 Tree Map Representation: Distribution by Type of Product and Company Size
Table 21.22 Scaffold Free Products: Distribution by Status of Development
Table 21.23 Scaffold Free Products: Distribution by Type of Product
Table 21.24 Scaffold Free Products: Distribution by Source of 3D Cultured Cells
Table 21.25 Scaffold Free Products: Distribution by Method Used for Fabrication
Table 21.26 Scaffold Free Products: Distribution by Material Used for Fabrication
Table 21.27 Scaffold Free Products: Distribution by Type of Product and Source of 3D Cultured Cells
Table 21.28 Scaffold Free Products: Distribution by Type of Product and Method Used for Fabrication
Table 21.29 Scaffold Free Product Developers: Distribution by Year of Establishment
Table 21.30 Scaffold Free Product Developers: Distribution by Company Size
Table 21.31 Scaffold Free Product Developers: Distribution by Location of Headquarters
Table 21.32 Leading Developers: Distribution by Number of Scaffold Free Products
Table 21.33 Tree Map Representation: Distribution by Type of Product and Company Size
Table 21.34 3D Bioreactors: Distribution by Type of 3D Bioreactor
Table 21.35 3D Bioreactors: Distribution by Working Volume
Table 21.36 3D Bioreactor Developers: Distribution by Year of Establishment
Table 21.37 3D Bioreactor Developers: Distribution by Company Size
Table 21.38 3D Bioreactor Developers: Distribution by Location of Headquarters
Table 21.39 Leading Developers: Distribution by Number of 3D Bioreactors
Table 21.40 3D Cell Culture Systems: Distribution by Key Application Areas
Table 21.41 3D Cell Culture Systems: Distribution by Key Application Areas and 3D Cell Culture Format
Table 21.42 Scaffold Based Products: Distribution by Key Application Areas
Table 21.43 Scaffold Free Products: Distribution by Key Application Areas
Table 21.44 3D Bioreactors: Distribution by Key Application Areas
Table 21.45 Funding and Investments: Distribution of Recipient Companies by Year of Establishment and Type of Funding, 2015 - 2021
Table 21.46 Funding and Investments: Cumulative Number of Instances by Year, 2015 - 2021
Table 21.47 Funding and Investments: Cumulative Amount Invested, 2015 - 2021 (USD Million)
Table 21.48 Funding and Investments: Distribution of Instances by Type of Funding, 2015 -2021
Table 21.49 Funding and Investments: Year-Wise Distribution by Number of Instances and Type of Funding, 2015 - 2021
Table 21.50 Funding and Investments: Distribution of Amount Invested by Type of Funding, 2015 - 2021 (USD Million)
Table 21.51 Funding and Investments: Year-Wise Distribution of Amount Invested and Type of Funding, 2015 -2021
Table 21.52 Funding and Investments: Distribution of Instances and Amount Invested by 3D Cell Culture Format, 2015 - 2021
Table 21.53 Funding and Investments: Distribution of Instances and Amount Invested by Type of Product, 2015 - 2021
Table 21.54 Funding and Investments: Distribution by Geography
Table 21.55 Funding and Investments: Regional Distribution by Total Amount Invested, 2015 - 2021
Table 21.56 Most Active Players: Distribution by Number of Funding Instances, 2015 - 2021
Table 21.57 Most Active Players: Distribution by Amount Raised, 2015 - 2021 (USD Million)
Table 21.58 Most Active Investors: Distribution by Funding Instances, 2015 - 2021
Table 21.59 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015 - 2021
Table 21.60 Partnerships and Collaborations: Distribution by Type of Partnership
Table 21.61 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 21.62 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Table 21.63 Partnerships and Collaborations: Distribution by Type of Partner
Table 21.64 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 21.65 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 21.66 Partnerships and Collaborations: Distribution by 3D Cell Culture Format
Table 21.67 Partnerships and Collaborations: Distribution by Year of Partnership and 3D Cell Culture Format
Table 21.68 Partnerships and Collaborations: Distribution by Type of Partnership and 3D Cell Culture Format
Table 21.69 Partnerships and Collaborations: Distribution by Type of Product
Table 21.70 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
Table 21.71 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 21.72 Most Active Players: Distribution by Number of Partnerships
Table 21.73 Partnerships and Collaborations: Regional Distribution
Table 21.74 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 21.75 Patent Analysis: Distribution by Type of Patent
Table 21.76 Patent Analysis: Cumulative Distribution by Publication Year, 2016 - Q1 2022
Table 21.77 Patent Analysis: Distribution of Granted Patents by Publication Year, 2016-Q1 2022
Table 21.78 Patent Analysis: Distribution of Filed Patents Publication Year, 2016-Q1 2022
Table 21.79 Patent Analysis: Distribution by Number of Patent Type and Publication Year, 2016-Q1 2022
Table 21.80 Patent Analysis: Distribution by Issuing Authorities Involved
Table 21.81 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2016-Q1 2022
Table 21.82 Leading Industry Players: Distribution by Number of Patents
Table 21.83 Leading Non-Industry Players: Distribution by Number of Patents
Table 21.84 Patent Analysis: Distribution by Patent Age, 2002-2022
Table 21.85 Patent Analysis: Valuation Analysis
Table 21.86 Publication Analysis: Distribution by Publication Year, 2019-Q1 2022
Table 21.87 Top Authors: Analysis by Number of Publications
Table 21.88 Patent Analysis: Key Journals based on Number of Publications
Table 21.89 Patent Analysis: Key Publisher based on Number of Publications
Table 21.90 Leading Funding Institute: Distribution by Number of Publications
Table 21.91 Global 3D Cell Culture Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.92 Global 3D Cell Culture Market: Distribution by Business Segment, 2022 and 2035
Table 21.93 3D Cell Culture Systems Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.94 3D Cell Culture Consumables Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.95 3D Cell Culture Services Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.96 Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format, 2022 and 2035
Table 21.97 3D Cell Culture Systems Market for Scaffold based Products, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.98 3D Cell Culture Systems Market for Scaffold Free Products, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.99 3D Cell Culture Systems Market for Market 3D Bioreactors, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.100 Global 3D Cell Culture Systems Market: Distribution by Type of Product, 2022 and 2035
Table 21.101 3D Cell Culture Systems Market for Attachment Resistant Surfaces, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.102 3D Cell Culture Systems Market for Hydrogels / ECMs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.103 3D Cell Culture Systems Market for Micropatterned Surface, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.104 3D Cell Culture Systems Market for Microcarriers, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.105 3D Cell Culture Systems Market for Microfluidic Systems, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.106 3D Cell Culture Systems Market for Solid Scaffolds, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.107 3D Cell Culture Systems Market for Suspension Culture Systems, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.108 Global 3D Cell Culture Systems Market: Distribution by Area of Application, 2022 and 2035
Table 21.109 3D Cell Culture Systems Market for Cancer Research, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.110 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.111 3D Cell Culture Systems Market for Stem Cell Research, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.112 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.113 Global 3D Cell Culture Systems Market: Distribution by Purpose, 2022 and 2035
Table 21.114 3D Cell Culture Systems Market for Research Use, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.115 3D Cell Culture Systems Market for Therapeutic Use, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.116 Global 3D Cell Culture Systems Market: Distribution by Geography, 2022 and 2035
Table 21.117 3D Cell Culture Systems Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.118 3D Cell Culture Systems Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.119 3D Cell Culture Systems Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.120 3D Cell Culture Systems Market in Latin America, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Million)
Table 21.121 3D Cell Culture Systems Market in Middle East and North Africa (MENA), Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.122 3D Cell Culture Systems Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.123 Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2022
Table 21.124 Global 3D Cell Culture Systems Market: Conservative, Base and Optimistic Scenarios, 2022, 2028 and 2035 (USD Million)
Table 21.125 Survey Insights: Distribution of Respondents by Year of Establishment of Company
Table 21.126 Survey Insights: Distribution of Respondents by Company Size
Table 21.127 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Region-Wise)
Table 21.128 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
Table 21.129 Survey Insights: Distribution of Respondents by Designation and Seniority Level
Table 21.130 Survey Insights: Distribution by Focus Area
Table 21.131 Survey Insights: Distribution by Type of 3D Cell Culture Products Offered
Table 21.132 Survey Insights: Distribution by Development Status of Product(s)
Table 21.133 Survey Insights: Distribution by Method of Fabrication Used
Table 21.134 Survey Insights: Distribution by Source of Cultured Cells
Table 21.135 Survey Insights: Distribution by Key Application Areas
Table 21.136 Survey Insights: Distribution by 3D Cell Culture Services Offered
Table 21.137 Survey Insights: Distribution by Current and Future Market Opportunity, 2022 and 2035

Companies Mentioned

  • 101Bio
  • 3D Biomatrix
  • 3D Biotechnology Solutions
  • 3D Biotek
  • 3Dnamics
  • 4Dcell
  • 4titude
  • AbbVie Ventures
  • abc biopply
  • Abcam
  • ABL Europe
  • Åbo Akademi University
  • Abstraction Ventures
  • Abzena
  • Accellta
  • Accurate International Biotechnology
  • Advanced BioMatrix
  • Advanced Regenerative Manufacturing Institute (ARMI)/BiofabUSA
  • Advanced Scientifics
  • Aetos Biologics
  • Afirmus Biosource
  • AGC
  • Agency for Science, Technology and Research (A*STAR)
  • AIM Biotech
  • Akero Therapeutics
  • Akron Biotech
  • Alector
  • Allevi
  • Alnylam Pharmaceuticals
  • Alphabioregen
  • ALS Investment Fund
  • AlveoliX
  • American Laboratory Products
  • AMS Biotechnology
  • AnaPath Services
  • Angel Investors
  • AngelMD
  • Angels 5K
  • Angels in MedCity
  • Angels Santé
  • Anthrogenesis
  • Aquitaine Science Transfert
  • Aquiti Gestion
  • AR Brown
  • Arizona State University
  • ARL Design
  • ARTeSYN Biosolutions
  • AS ONE INTERNATIONAL
  • AstraZeneca
  • Arizona State University
  • ATEL Ventures
  • Atera
  • Avantor
  • Axol Bioscience
  • AxoSim
  • AXT
  • Axxicon
  • BASF
  • Bayer
  • B-CULTURE
  • BEOnChip
  • Bi/ond
  • Bio-Byblos Biomedical
  • BioCat
  • BioConcept
  • BIOFABICS
  • Biogelx
  • Bioinspired Solutions
  • BioInvent International
  • BIOKÉ
  • BioLamina
  • Biomaterials USA
  • Biomerix
  • BiomimX
  • Biopredic International
  • Bio-Techne
  • BioTek Instruments
  • BISS TGT
  • Barcelona Liver Bioservices (BLB)
  • Bonus BioGroup
  • Bpifrance
  • BRAIN
  • BrainXell
  • Brammer Bio
  • Braveheart Investment Group
  • Bristol-Myers Squibb
  • Broad Institute
  • BRTI Life Sciences
  • Cambridge Bioscience
  • CarThera
  • Cedars-Sinai Medical Center
  • Celartia
  • Cell Applications
  • Cell Culture Company (C3)
  • CellFiber
  • Cell Guidance Systems
  • CELLEC Biotek
  • Cellendes
  • Cellevate
  • CELLnTEC
  • CELLphenomics
  • CellSpring
  • CellSystems
  • Celprogen
  • CelVivo
  • Center for Drug Evaluation and Research (CDER)
  • Center for the Advancement of Science in Space (CASIS)
  • CESCO Bioengineering
  • Charles River Laboratories
  • Cherry Biotech
  • China Regenerative Medicine International (CRMI)
  • Cincinnati Children's Hospital Medical Center
  • CITIC Securities
  • CN Bio Innovations
  • CN Innovations
  • Collagen Solutions
  • Commission for Technology and Innovation
  • Commonwealth Serum Laboratories
  • Comune di Milano
  • Corning Life Sciences
  • Cosmo Bio
  • Creative Bioarray
  • CSL
  • Curi Bio
  • Cyprio
  • Cyprotex
  • Cytiva
  • Danaher
  • Deepbridge Capital
  • Demcon
  • Development Bank of Wales
  • DiPole Materials
  • Downing Ventures
  • Dynamic42
  • EBERS
  • Ectica Technologies
  • EDITHGEN
  • EDmicBio
  • Electrospinning
  • Emulate
  • Enso Discoveries
  • eNUVIO
  • Eppendorf
  • Esco Aster
  • Esperante
  • Ethicon
  • Etica Technologies
  • European Commission
  • European Life Sciences Growth Fund (ELSGF)
  • European Research Council (ERC)
  • European Union (EU)
  • Eurostars
  • EU-ToxRisk
  • Eva Scientific
  • Evotec
  • Executive Agency for Small and Medium-sized Enterprises (EASME)
  • faCellitate
  • Food and Drug Administration
  • Fennik Life Sciences
  • Ferentis
  • FHNW University
  • FiberCell Systems
  • Fibralign
  • Finep
  • Finesse Solutions
  • Finovam Gestion
  • Flexcell International
  • Fundação para a Ciência e a Tecnologia (FCT)
  • Foundation for Technological Innovation
  • Founder
  • Founders Fund
  • Freeline
  • French Government
  • Frequency Therapeutics
  • FroggaBio
  • Fujifilm
  • FUJIFILM Wako Pure Chemical
  • Funakoshi
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
  • Gabriel Investments
  • Galapagos
  • Galia Gestion
  • Gamma 3
  • Gelmetix
  • Gelomics
  • Gemini Bio
  • Gemstone Biotherapeutics
  • Genome Institute of Singapore
  • Georgia Research Alliance
  • German Research Foundation
  • GlassWall Syndicate
  • GlaxoSmithKline
  • Global Cell Solutions
  • Government of China
  • Government of the Netherlands
  • Great Stuff Ventures
  • GSI
  • HµREL
  • Hamilton
  • Harvard Apparatus
  • Harvard College
  • HCS Pharma
  • Helvoet
  • Heraeus Medical
  • Hesperos
  • Histogenics
  • Hokkaido Soda
  • HP Wild Holding
  • Hubrecht Organoid Technology
  • Human Models for Analysis of Pathways (HMAPs) Center
  • Humanetics
  • Hyamedix
  • ibidi
  • IMSS-Gulf Bio Analytical
  • INITIO CELL
  • Innovate UK
  • Innovation Fund Denmark
  • InoCure
  • Inova Health System
  • inRegen
  • InSphero
  • Institute for Molecular Medicine Finland
  • Invest Northern Ireland
  • Invitrocue
  • InvivoSciences
  • Ionis Pharmaceuticals
  • Irdi Soridec Gestion
  • Janssen Biotech
  • Japan Vilene Company
  • Jellagen Marine Biotechnologies
  • Johns Hopkins University
  • JRI Orthopaedics
  • JVCKENWOOD
  • Kero
  • Kim & Friends
  • Kirkstall
  • KIYATEC
  • KOKEN
  • Koninklijke Nederlandse Akademie Van Wetenschappen
  • Kuraray
  • LabCorp
  • Laboratory for Integrated Micro Mechatronic Systems
  • Laconia
  • LAMBDA Laboratory Instruments
  • Lantern Pharma
  • Lawrence J. Ellison Institute for Transformative Medicine
  • LBA Healthcare Management
  • Lena Biosciences
  • LFB Biomanufacturing
  • Life Technologies
  • Lifecore Biomedical
  • LifeNet Health
  • Laboratory for Integrated Micro-Mechatronic Systems (LIMMS)
  • Lineage Cell Therapeutics
  • Locate Bio
  • London School of Hygiene & Tropical Medicine
  • Lonza
  • Lund University
  • LuoLabs
  • Manchester BIOGEL
  • Mario Negri Institute for Pharmacological Research
  • Maryland Momentum Fund
  • Maryland Stem Cell Research Fund (MSCRF)
  • Massachusetts Institute of Technology
  • MassChallenge
  • MatTek Life Sciences
  • MBL International
  • Menicon Life Science
  • Merck Accelerator
  • Merck KGaA
  • Michael J. Fox Foundation
  • Michigan Technological University
  • MicorFIT
  • MicroDigital
  • Micronit
  • MicroTissues
  • Midven
  • MIMETAS
  • Minerva Business Angel Network
  • Ministry of Higher Education, Research and Innovation (France)
  • Mirage Biomedicals
  • Molecular Devices
  • MTTlab
  • Nano Dimension
  • Nanobiose
  • Nanofiber Solutions
  • Nanogaia
  • NanoSurface Biomedical
  • National Aeronautics and Space Administration (NASA)
  • National Cancer Institute (NCI)
  • National Center for Advancing Translational Sciences (NCATS)
  • National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)
  • National Institutes of Health (NIH)
  • National Institute on Aging (NIA)
  • National Institutes for Food and Drug Control (NIFDC)
  • National Natural Science Foundation of China
  • National Science Foundation (NSF)
  • National University Hospital
  • National University of Singapore
  • NETRI
  • Neuromics
  • New Orleans BioFund
  • Newable Private Investing
  • Nexcelom Bioscience
  • Nichirei Biosciences
  • Nord France Amorquage
  • Northwick Park Institute for Medical Research
  • Nortis
  • Nova Biomedical
  • Novartis Venture Fund
  • Noviocell
  • Nucleus Biologics
  • NYU Winthrop Hospital
  • Olaregen Therapeutix
  • Omni Life Science
  • Oregon Health & Science University
  • Organovo
  • Orthomimetics
  • OS Fund
  • Oxford MEStar
  • Pairnomix
  • Pall Corporation
  • Particle3D
  • Path BioAnalytics
  • PBS Biotech
  • Peak Capital Advisors
  • Pelo Biotech
  • Pensees
  • PepGel
  • Percell Biolytica
  • PerkinElmer
  • Pfizer
  • Phase Holographic Imaging (PHI)
  • Pitch@Palace
  • PL BioScience
  • Plasticell
  • Pluristem Therapeutics
  • Portugal Ventures
  • Precision Biologics
  • Premedical Laboratories
  • Primorigen Biosciences
  • Principia SGR
  • ProBio
  • ProBioGen
  • Prodizen
  • PromoCell
  • Protista International
  • PT Rajawali Medika Mandiri
  • QGel Bio
  • QIAGEN 
  • Quintech Life Sciences
  • RASA
  • React4life
  • Real Research
  • RealBio Technology
  • Regemat3D
  • Repligen
  • ReproCell
  • Research Without Animal Experiment
  • Revivocell
  • Rigenerand
  • Roche
  • RoosterBio
  • Roswell Park Comprehensive Cancer Center
  • Royal Netherlands Academy of Arts and Sciences
  • Saguaro Technologies
  • SAICO Biosystems
  • Sanofi Ventures
  • SARSTEDT
  • Sartorius
  • S-BIO
  • Science and Technology Facilities Council (STFC)
  • ScienCell
  • ScienCell Research Laboratories
  • SciFi VC
  • SciKon Innovation
  • Scinus Cell Expansion
  • Scottish Investment Bank
  • ScreenIn3D
  • Seres Therapeutics
  • Shanghai Cienle Medical Technology
  • Shanghai Institute of Biochemistry and Cell Biology (SIBCB)
  • Shanghai Institute of Materia Medica
  • Siemens Technology
  • Sigma-Aldrich
  • SKE Research Equipment
  • SmiLe Incubator
  • SoloHill Engineering
  • Sphere Fluidics
  • Spheritech
  • Spiber Technologies
  • Stanford University
  • Start-Up Chile
  • State Key Laboratory of Experimental Hematology
  • StemCell Systems
  • STEMCELL Technologies
  • Stemmatters
  • StemoniX
  • StemTek Therapeutics
  • SUN bioscience
  • Swiss Federal Laboratories for Materials Science and Technology
  • SyndicateRoom
  • Synthecon
  • SynVivo
  • TA Instruments
  • Takeda
  • Tampere University
  • Tantti Laboratory
  • tebu-bio
  • Technical University of Berlin
  • TEDCO
  • Terumo
  • Texas Tech University Health Sciences Center  (TTUHSC) 
  • The Idea Village
  • Mario Negri Institute for Pharmacological Research
  • Thermo Fisher Scientific
  • TheWell Bioscience
  • Tianjin Weikai Biological Engineering
  • Tissue Click
  • TissueLabs
  • TissUse
  • Tokyo Future Style
  • TPG
  • TreeFrog Therapeutics
  • Trevigen
  • Triumvirate Environmental
  • Twinhelix
  • U.S. Small Business Administration (SBA)
  • UK Innovation & Science Seed Fund
  • UK Science and Technology Facilities Council
  • United States Department of Defense
  • University College London
  • University Hospital Zurich (USZ)
  • University of Alberta
  • University of Arkansas for Medical Sciences
  • University of Bath
  • University of Brescia
  • University of Bristol
  • University of California
  • University of Cambridge
  • University of Central Florida
  • University of Genoa
  • University of Manchester
  • University of Mannheim
  • University of Milan
  • University of Nottingham
  • University of Sheffield
  • University of Strathclyde
  • University of Washington School of Pharmacy
  • University of Zurich
  • UPM Biomedicals
  • UW Medicine
  • VA Portland Health Care System
  • Vanderbilt University
  • Venture Kick
  • Venturecraft
  • VentureSouth
  • Viscofan BioEngineering
  • Visikol
  • Vivo Biosciences
  • VWR
  • Wake Forest Institute for Regenerative Medicine
  • Women Who Tech
  • XAnge
  • Xenos
  • XP Biomed
  • Xylyx Bio
  • Zhejiang University
  • zPREDICTA

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

3D Cell Cultures: Technologies and Global Markets - Product Image

3D Cell Cultures: Technologies and Global Markets

  • Report
  • 442 Pages
  • Global
From
Global 3D Cell Culture Market Size, Share & Trends Analysis Report by Technology (Scaffold Based, Scaffold Free, Bioreactors, Microfluidics, Bioprinting), Application, End-use, Region, and Segment Forecasts, 2024-2030 - Product Image

Global 3D Cell Culture Market Size, Share & Trends Analysis Report by Technology (Scaffold Based, Scaffold Free, Bioreactors, Microfluidics, Bioprinting), Application, End-use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 125 Pages
  • Global
From
Global 3D Cell Culture Market Report by Product, Application, End User, and Region 2023-2028 - Product Image

Global 3D Cell Culture Market Report by Product, Application, End User, and Region 2023-2028

  • Report
  • 141 Pages
  • Global
From
3D Cell Culture Technologies Global Market Report 2024 - Product Image

3D Cell Culture Technologies Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
3D Cell Culture - Global Strategic Business Report - Product Image

3D Cell Culture - Global Strategic Business Report

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.